Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AYTU NASDAQ:FNCH NASDAQ:QTTB NASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.26-3.4%$2.34$0.95▼$2.85$21.01M0.2279,085 shs43,691 shsFNCHFinch Therapeutics Group$12.70+0.8%$12.66$10.15▼$15.85$20.40M1.192,173 shs631 shsQTTBQ32 Bio$1.66-2.9%$1.92$1.35▼$53.79$20.86M0.07105,925 shs52,185 shsSLXNSilexion Therapeutics$7.05-1.3%$9.96$6.51▼$189.00$5.23M0.0422,222 shs19,711 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-3.42%-2.16%-8.87%+13.00%-5.44%FNCHFinch Therapeutics Group+0.79%-2.31%+3.34%-6.39%-3.93%QTTBQ32 Bio-2.92%-6.21%-16.16%-12.63%-96.04%SLXNSilexion Therapeutics-1.33%-8.98%-20.49%-50.34%-94.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYTUAytu BioPharma$2.26-3.4%$2.34$0.95▼$2.85$21.01M0.2279,085 shs43,691 shsFNCHFinch Therapeutics Group$12.70+0.8%$12.66$10.15▼$15.85$20.40M1.192,173 shs631 shsQTTBQ32 Bio$1.66-2.9%$1.92$1.35▼$53.79$20.86M0.07105,925 shs52,185 shsSLXNSilexion Therapeutics$7.05-1.3%$9.96$6.51▼$189.00$5.23M0.0422,222 shs19,711 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYTUAytu BioPharma-3.42%-2.16%-8.87%+13.00%-5.44%FNCHFinch Therapeutics Group+0.79%-2.31%+3.34%-6.39%-3.93%QTTBQ32 Bio-2.92%-6.21%-16.16%-12.63%-96.04%SLXNSilexion Therapeutics-1.33%-8.98%-20.49%-50.34%-94.67%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYTUAytu BioPharma$81M0.25N/AN/A$4.64 per share0.49FNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AQTTBQ32 Bio$1.16M17.46N/AN/A$0.47 per share3.53SLXNSilexion TherapeuticsN/AN/AN/AN/A($37.31) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYTUAytu BioPharma-$15.84M-$0.72N/A∞N/A2.37%3.51%0.91%9/25/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AQTTBQ32 Bio-$47.73M-$4.30N/AN/AN/AN/A-2,709.70%-61.16%11/6/2025 (Estimated)SLXNSilexion Therapeutics-$16.44MN/A0.00∞N/AN/AN/A-355.74%N/ALatest SLXN, QTTB, FNCH, and AYTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025AYTUAytu BioPharma-$0.02N/AN/AN/AN/AN/A8/12/2025Q2 2025SLXNSilexion Therapeutics-$3.15-$4.32-$1.17-$4.32N/AN/A8/6/2025Q2 2025QTTBQ32 Bio-$1.14-$0.78+$0.36-$0.78N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYTUAytu BioPharmaN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYTUAytu BioPharma0.271.030.87FNCHFinch Therapeutics GroupN/A3.873.87QTTBQ32 Bio1.685.065.06SLXNSilexion Therapeutics26.582.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYTUAytu BioPharma33.49%FNCHFinch Therapeutics Group21.77%QTTBQ32 Bio31.32%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipAYTUAytu BioPharma3.60%FNCHFinch Therapeutics Group44.90%QTTBQ32 Bio40.00%SLXNSilexion Therapeutics6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAYTUAytu BioPharma1608.98 million8.65 millionNot OptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataQTTBQ32 Bio3912.20 million7.32 millionN/ASLXNSilexion TherapeuticsN/A730,000688,000N/ASLXN, QTTB, FNCH, and AYTU HeadlinesRecent News About These CompaniesSilexion Therapeutics selects AMS as CRO for SIL204 Phase 2/3 trialsSeptember 4 at 6:52 PM | msn.comSilexion Therapeutics Selects AMS Advanced Medical Services as CRO to Support SIL204 Phase 2/3 Clinical Trials Following Promising Preclinical ResultsSeptember 4 at 9:31 AM | quiverquant.comQSilexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204September 4 at 9:25 AM | globenewswire.comSilexion Therapeutics Corp. to Present at 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2 at 8:51 AM | quiverquant.comQSilexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment ConferenceSeptember 2 at 8:45 AM | globenewswire.comSilexion Therapeutics Executes Reverse Stock SplitAugust 22, 2025 | msn.comSilexion Therapeutics Increases Authorized Share CapitalAugust 19, 2025 | tipranks.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports Second Quarter 2025 Financial Results and Preclinical Advancements in RNAi Therapies for KRAS-Driven CancersAugust 12, 2025 | quiverquant.comQSilexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 12, 2025 | globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross ProceedsJuly 31, 2025 | globenewswire.comSilexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS MutationJuly 31, 2025 | globenewswire.comSilexion Therapeutics Holds Annual General MeetingJuly 17, 2025 | theglobeandmail.comSilexion Therapeutics Announces 1-for-15 Reverse Share SplitJuly 16, 2025 | globenewswire.comSilexion Therapeutics Corp. Reports Positive Preclinical Data for ...July 11, 2025 | nasdaq.comSilexion Therapeutics Announces Positive Results in Preclinical Study ...July 11, 2025 | morningstar.comMSilexion Therapeutics receives Nasdaq panel approval for continued listingJuly 9, 2025 | uk.investing.comSilexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell LinesJuly 9, 2025 | globenewswire.comSilexion Therapeutics announces preclinical results on SIL204May 30, 2025 | finance.yahoo.comSilexion Therapeutics Corp (SLXN)’s RNAi Therapy Blocks 90% of Colorectal TumorsMay 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLXN, QTTB, FNCH, and AYTU Company DescriptionsAytu BioPharma NASDAQ:AYTU$2.26 -0.08 (-3.42%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$2.23 -0.03 (-1.33%) As of 09/4/2025 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.Finch Therapeutics Group NASDAQ:FNCH$12.70 +0.10 (+0.79%) As of 09/4/2025 11:10 AM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Q32 Bio NASDAQ:QTTB$1.66 -0.05 (-2.92%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$1.70 +0.05 (+2.71%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Silexion Therapeutics NASDAQ:SLXN$7.04 -0.10 (-1.33%) Closing price 09/4/2025 03:51 PM EasternExtended Trading$7.14 +0.09 (+1.28%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
